行情

AMPE

AMPE

安皮奥制药
AMEX

实时行情|Nasdaq Last Sale

1.690
-0.080
-4.52%
盘后: 1.700 +0.01 +0.59% 18:02 09/28 EDT
开盘
1.740
昨收
1.770
最高
1.755
最低
1.680
成交量
109.21万
成交额
--
52周最高
2.980
52周最低
0.7208
市值
3.39亿
市盈率(TTM)
-21.0199
分时
5日
1月
3月
1年
5年
Ampio Pharmaceuticals 获得美国专利,名为“治疗与呼吸道病毒相关的疾病的方法”
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5276&f=G&l=50&d=PTXT&p=106&S1=20210928&OS=20210928&RS=20210928
Benzinga · 12小时前
Ampio 将在印度测试吸入性 COVID-19 治疗
Benzinga · 09/21 19:46
Ampio 获得印度监管机构批准,开始对 COVID-19 相关呼吸窘迫的吸入 Ampion 进行中期研究
MT Newswires · 09/21 15:06
BRIEF-Ampio Pharmaceuticals Inc Receives Approval From The Drugs Controller General Of India (DCGI) To Commence AP-019 Phase II Study In India
reuters.com · 09/21 13:17
Ampio Pharma 报告获得印度药品监管总局的批准,开始在印度开展 AP-019 2 期研究
 Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs
Benzinga · 09/21 13:17
Ampio Pharmaceuticals 获得印度药品监管总局 (DCGI) 的批准,可在印度开展 AP-019 II 期研究
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) o...
PR Newswire · 09/21 13:15
为什么 Ampio Pharmaceuticals 的股票今天交易更高
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in patients suffering from severe osteoarthritis of the knee (OAK).
Benzinga · 09/15 18:54
YY、NNVC 和 REKR 处于午盘走势中
Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals (NYSE:ATNM) +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. S...
Seekingalpha · 09/15 17:41
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AMPE最新的财务预测,通过AMPE每股收益,每股净资产,每股现金流等数据分析安皮奥制药近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测AMPE价格均价为4.000,最高价位4.000,最低价为4.000。
最高4.000
均价4.000
最低4.000
现价1.690
EPS
实际EPS
预期EPS
-0.02-0.01-0.01-0.00
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
机构持股
总机构数: 82
机构持股: 2,094.23万
持股比例: 10.45%
总股本: 2.00亿
类型机构数股数
增持
13
136.43万
建仓
15
834.75万
减持
18
705.39万
平仓
15
145.97万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-3.50%
制药与医学研究
-1.90%
高管信息
Chairman/Chief Executive Officer/Director
Michael Macaluso
Chief Financial Officer/Treasurer/Secretary
Daniel Stokely
Chief Operating Officer
Holli Cherevka
Director
David Bar-Or
Independent Director
Philip Coelho
Independent Director
Richard Giles
Independent Director
David Stevens
暂无数据
AMPE 简况
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. The Company's lead product candidate is Ampion, which contains a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease. Ampion is in development as an intra-articular injection treatment for severe osteoarthritis of the knee (OAK), an intravenous (IV) treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress. The Company is in the process of advancing clinical trials of Ampion in the United States. Ampion targets the cellular pathways in the innate immune response correlated with pain, inflammation, and joint damage in osteoarthritis.

微牛提供Ampio Pharmaceuticals Inc(AMEX-AMPE)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AMPE股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AMPE股票基本功能。